Stockscreener 앱 받기
132.56
0.62%
0.82
시간 외 거래:
132.56
Neurocrine Biosciences Inc 주식(NBIX)의 최신 뉴스
What Neurocrine Biosciences (NBIX)'s New Senior TD Data and Guidelines Could Mean For Shareholders - simplywall.st
NBIX Technical Analysis & Stock Price Forecast - intellectia.ai
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Neurocrine Biosciences Inc (NBIX) Shares Up 3.15% on Mar 31 - GuruFocus
Responsive Playbooks and the NBIX Inflection - Stock Traders Daily
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
Neurocrine Biosciences Inc (NBIX) Shares Down 3.14% on Mar 30 - GuruFocus
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurocrine Biosciences Stock: A Leader in Neurological and Endocrine Therapies with Strong US Market - AD HOC NEWS
Wealth Enhancement Advisory Services LLC Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Free cash flow per share of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
SG Americas Securities LLC Buys 119,339 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Nordea Investment Management AB Increases Stake in Neurocrine Biosciences, Inc. $NBIX - marketbeat.com
Assenagon Asset Management S.A. Has $11.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - marketbeat.com
[SCHEDULE 13G/A] NEUROCRINE BIOSCIENCES INC Amended Passive Investment Disclosure - stocktitan.net
Neurocrine (NASDAQ:NBIX) Expands Clinical Strategy As Nasdaq Futures Shift - Kalkine Media
Tudor Investment Corp ET AL Buys 23,893 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - chartmill.com
Is Geriatric-Focused INGREZZA Data Quietly Reframing Neurocrine Biosciences' Neurology Leadership Narrative (NBIX)? - Yahoo Finance
Neurocrine Biosciences Updates Tardive Dyskinesia Care And Valuation Story - simplywall.st
Neurocrine presents tardive dyskinesia treatment guidance for elderly - StreetInsider
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings - PR Newswire
Neurocrine Biosciences Inc (NBIX) Shares Up 3.53% on Mar 25 - GuruFocus
Earnings Miss: Why is Neurocrine Biosciences Inc stock going upProfit Target & Consistent Growth Equity Picks - baoquankhu1.vn
Shorts Report: Does Neurocrine Biosciences Inc have pricing powerTrend Reversal & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup - chartmill.com
Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update - MSN
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Neurocrine Biosciences, Inc.Common Stock (NQ: NBIX - FinancialContent
CIBC Private Wealth Group Boosts Neurocrine Biosciences Stock Holdings - National Today
CIBC Private Wealth Group LLC Grows Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assessing Neurocrine Biosciences (NBIX) Valuation As Shares Soften Despite Growing Revenue And Net Income - Sahm
Block Trades: Can Neurocrine Biosciences Inc be recession proofProfit Target & Long Hold Capital Preservation Plans - baoquankhu1.vn
Hedge Fund Bets: Can Neurocrine Biosciences Inc maintain its current growth rateWall Street Watch & Safe Entry Trade Signal Reports - baoquankhu1.vn
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hudson Bay Capital Management LP - marketbeat.com
If You Invested $1,000 in Neurocrine Biosciences Inc (NBIX) - stocktitan.net
Neurocrine Biosciences Maps 2026 Execution, “Data-Rich” 2027; Ingrezza Guides $2.7B–$2.8B - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Case as a Quality Value Stock - ChartMill
Eric Topol boards Flagship as advisor—Chutes & Ladders - fiercebiotech.com
Understanding the Setup: (NBIX) and Scalable Risk - Stock Traders Daily
Wolfe Research initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendation - MSN
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Neurocrine Biosciences promotes Andrew Ratz to operations chief By Investing.com - Investing.com South Africa
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Tec - GuruFocus
Neurocrine at Stifel CNS Forum: Growth and Strategic Focus - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2026 Virtual CNS Forum, Mar-17-2026 04 - marketscreener.com
Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants - Stock Titan
Neurocrine Biosciences promotes Andrew Ratz to operations chief - Investing.com
Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer - StreetInsider
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer - StreetInsider
3.38%
0.89%
자본화:
|
볼륨(24시간):